Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics is well positioned in the growing diagnostic testing market, with a strong national network of patient service centers and partnerships with key healthcare players. The company's recent addition of independent dialysis clinic clients and collaborative lab solutions for Corewell contribute to its continued growth, and its clinical trials testing and information technology solutions segment provide potential for future expansion. Additionally, strong fiscal year 2026 guidance indicates robust demand in the core clinical testing segment, with expected growth driven by organic factors such as advanced diagnostics and early detection/screening. Overall, we believe the company's strong financial performance and strategic initiatives make it a solid investment opportunity.

Quest Diagnostics is seeing a solid increase in revenue, adjusted EPS, and AOI, with a margin of 15.3%, which has decreased by approximately 30bps year-over-year due to expenses related to FMS, Corewell start-up costs, and Project Nova investments. However, these expenses were offset by increased total revenue of $2.81B, representing a +7.1% year-over-year and +6.4% organic growth. Total volumes also saw a significant increase of +8.5%, well above the +5.8%E estimate.